References
- Aronsohn, A., & Jensen, D. (2012). Informed deferral: A moral requirement for entry into the hepatitis C virus treatment warehouse. Hepatology, 56(5), 1591–1592. doi:10.1002/hep.25957
- Barua, S., Greenwald, R., Grebely, J., Dore, G. J., Swan, T., & Taylor, L. E. (2015). Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Annals of Internal Medicine, 163(3), 215–223. doi:10.7326/M15-0406
- Castera, L., Winnock, M., Pambrun, E., Paradis, V., Perez, P., Loko, M. A., & Salmon, D. (2014). Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration. HIV Medicine, 15(1), 30–39. doi:10.1111/hiv.12082
- Centers for Medicare and Medicaid Services. (n.d.). Medicaid drug rebate program. Retrieved from https://www.medicaid.gov/medicaid-chip-program-information/by-topics/benefits/prescription-drugs/medicaid-drug-rebate-program.html
- Chhatwal, J., Kanwal, F., Roberts, M. S., & Dunn, M. A. (2015). Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Annals of Internal Medicine, 162(6), 397–406. doi:10.7326/M14-1336
- Connecticut Department of Social Services. (n.d.-a). Connecticut Medicaid Preferred Drug List. Retrieved from https://www.ctdssmap.com/CTPortal/Portals/0/StaticContent/Publications/CT_PDL_medicaid.pdf
- Connecticut Department of Social Services. (n.d.-b). New hepatitis C prior authorization criteria – Sovaldi. Retrieved from http://www.huskyhealthct.org/providers/provider_postings/New_Hepatitis_C_Prior_Authorization_Criteria-Sovaldi.pdf
- Cousien, A., Tran, V. C., Deuffic-Burban, S., Jauffret-Roustide, M., Dhersin, J. S., & Yazdanpanah, Y. (2016). Hepatitis C treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs. Hepatology, 63(4), 1090–1101. doi:10.1002/hep.28227
- Dieperink, E., Pocha, C., Thuras, P., Knott, A., Colton, S., & Ho, S. B. (2014). All-cause mortality and liver-related outcomes following successful antiviral treatment for chronic hepatitis C. Digestive Diseases and Sciences, 59(4), 872–880. doi:10.1007/s10620-014-3050-5
- Do, A., Mittal, Y., Liapakis, A., Cohen, E., Chau, H., Bertuccio, C., & Lim, J. K. (2015). Drug authorization for sofosbuvir/ledipasvir (harvoni) for chronic HCV infection in a real-world cohort: A new barrier in the HCV care cascade. PLoS One, 10(8), e0135645. doi:10.1371/journal.pone.0135645
- Durham, D. P., Skrip, L. A., Bruce, R. D., Vilarinho, S., Elbasha, E. H., Galvani, A. P., & Townsend, J. P. (2016). The impact of enhanced screening and treatment on hepatitis C in the United States. Clinical Infectious Diseases, 62(3), 298–304. doi:10.1093/cid/civ894
- Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Goncales, F. L., Jr., … Yu, J. (2002). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine, 347(13), 975-982. doi:10.1056/NEJMoa020047
- Kowdley, K. V., Gordon, S. C., Reddy, K. R., Rossaro, L., Bernstein, D. E., Lawitz, E., & Investigators, I. O. N. (2014). Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. New England Journal of Medicine, 370(20), 1879–1888. doi:10.1056/NEJMoa1402355
- Linas, B. P., Morgan, J. R., Pho, M. T., Leff, J. A., Schackman, B. R., Horsburgh, C. R., … Kim, A. Y. (2017). Cost effectiveness and cost containment in the era of interferon-free therapies to treat hepatitis C virus genotype 1. Open Forum infectious Diseases, 4(1), ofw266. doi:10.1093/ofid/ofw266
- Lo Re, V., 3rd, Gowda, C., Urick, P. N., Halladay, J. T., Binkley, A., Carbonari, D. M., & Kostman, J. R. (2016). Disparities in absolute denial of modern hepatitis C therapy by type of insurance. Clinical Gastroenterology and Hepatology, 14(7), 1035–1043. doi:10.1016/j.cgh.2016.03.040
- Martin, N. K., Vickerman, P., Grebely, J., Hellard, M., Hutchinson, S. J., Lima, V. D., & Hickman, M. (2013). Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology, 58(5), 1598–1609. doi:10.1002/hep.26431
- Rein, D. B., Wittenborn, J. S., Smith, B. D., Liffmann, D. K., & Ward, J. W. (2015). The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus. Clinical Infectious Diseases, 61(2), 157–168. doi:10.1093/cid/civ220
- Singal, A. G., Volk, M. L., Jensen, D., Di Bisceglie, A. M., & Schoenfeld, P. S. (2010). A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clinical Gastroenterology and Hepatology, 8(3), 280–288. 288 e281. doi:10.1016/j.cgh.2009.11.018
- Veldt, B. J., Saracco, G., Boyer, N., Camma, C., Bellobuono, A., Hopf, U., & Schalm, S. W. (2004). Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut, 53(10), 1504–1508. doi:10.1136/gut.2003.038257
- Ward, J. W., & Mermin, J. H. (2015). Simple, effective, but out of reach? Public health implications of HCV drugs. New England Journal of Medicine, 373(27), 2678–2680. doi:10.1056/NEJMe1513245
- Yehia, B. R., Schranz, A. J., Umscheid, C. A., & Lo Re, V., 3rd. (2014). The treatment cascade for chronic hepatitis C virus infection in the United States: A systematic review and meta-analysis. PLoS One, 9(7), e101554. doi:10.1371/journal.pone.0101554
- Younossi, Z. M., Stepanova, M., Afdhal, N., Kowdley, K. V., Zeuzem, S., Henry, L., & Marcellin, P. (2015). Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. Journal of Hepatology, 63(2), 337–345. doi:10.1016/j.jhep.2015.03.014
- Zahnd, C., Salazar-Vizcaya, L., Dufour, J. F., Mullhaupt, B., Wandeler, G., Kouyos, R., & Swiss Hepatitis, C. C. S. (2016). Modelling the impact of deferring HCV treatment on liver-related complications in HIV coinfected men who have sex with men. Journal of Hepatology, 65(1), 26–32. doi:10.1016/j.jhep.2016.02.030